A balance of protein synthesis and degradation is tightly regulated in our bodies in order to
keep us healthy. Most intracellular proteins are degraded via the ubiquitinproteasome …

The ubiquitin-proteasome pathway regulates many basic cellular processes and has been
proven to be a promising target for cancer therapy. Bortezomib is the first US Food and Drug …

Despite the proven efficacy of proteasome inhibitors like bortezomib (BTZ) in multiple
myeloma, mantle cell lymphoma, and in an experimental setting in pediatric acute leukemia …

Head and neck squamous cell carcinomas (HNSCC) exhibit constitutive activation of
transcription factors nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), which are …

Purpose: Bortezomib is a peptide boronic acid inhibitor of the proteasome developed for
cancer therapy. The compound is being evaluated currently in Phase II and III clinical trials …

Bortezomib is a specific inhibitor of the S20 proteasome1 and acts as a prominent inducer of
apoptosis that is now clinically approved for the treatment of multiple myeloma. 2 Ongoing …

Proteasome inhibition with bortezomib (BTZ) is an effective treatment for hematological
malignancies and an emerging treatment strategy for acute leukemia. However, the side …

Background Drug combinations of the proteasome inhibitor bortezomib with cytotoxic
chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric …

Background Multiple myeloma (MM), a malignancy of plasma cells, is the second most
prevalent hematological cancer. Bortezomib is the most effective chemotherapeutic drug …

The proteasome inhibitor bortezomib, which induces cell death in various cancer cell lines
including lymphatic neoplasias, has recently been approved for the treatment of relapsed …